CRSP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CRISPR Therapeutics is not a clear buy right now for a Beginner investor with a long-term focus and $50,000-$100,000 to deploy. The stock has strong recent momentum and a favorable event catalyst from the FDA expanding Casgevy approval, but the fundamentals are still weak, insider selling is rising, and valuation support is not provided. For an impatient investor who does not want to wait for an ideal entry, this is still more of a hold than an immediate buy.
Technically, CRSP is in a bullish short-term posture. The stock closed at 59.85 after a strong regular-session gain of 8.02%, with price trading above the pivot at 56.616 and near resistance at 59.924 and 61.968. MACD histogram is positive and expanding, which supports upside momentum. However, RSI_6 is 79.086, indicating the stock is stretched and near overbought conditions. Moving averages are converging, suggesting the trend is improving but not yet firmly established for a clean long-term entry.
["FDA expanded Casgevy approval to children as young as two, increasing the addressable U.S. patient pool by about 5,500 children", "Analysts have generally been raising price targets over the last several weeks", "Options sentiment is bullish with low put-call ratios and unusually high call volume", "MACD is positive and expanding, showing strong near-term momentum", "The stock broke higher on the session and is trading above key pivot levels"]
["FY 2025 revenue fell 90% to $3.5 million", "Net loss for FY 2025 was about $581.6 million, showing poor current profitability", "Insiders are selling, with selling up 476.16% over the last month", "Hedge funds are neutral with no significant accumulation trend", "RSI is elevated, which makes the current entry less attractive for a long-term beginner investor"]
The latest financial data points to a weak latest reported year rather than a strong recent growth quarter. FY 2025 revenue collapsed 90% to $3.5 million, while net loss widened to about $581.6 million. That means the company is still in a commercialization and investment phase, and current growth trends are not yet strong on a fundamental basis. No reliable latest quarter seasonal breakdown was provided.
Analyst sentiment has improved overall. Morgan Stanley upgraded CRSP to Equal Weight from Underweight with a $60 target, citing better visibility on Casgevy launch and pipeline value. Bernstein raised its target to $56 and kept Market Perform. Evercore ISI and Citi remained bullish with targets of $76 and $82, while BofA trimmed its target slightly to $83 but kept Buy. Overall, Wall Street is constructive but mixed: the pros like the commercialization catalyst and pipeline optionality, while the cons remain centered on weak earnings, uncertain revenue recognition, and execution risk.
